MedTrace Logo

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

NCT01962935 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-06-25

No results posted yet for this study

Summary

Study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD).

Interventions

DRUG

AZD4721

Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily

DRUG

Placebo

Part A - multiple ascending dose daily

DRUG

AZD5069

Part B - one dose decided after part A, twice a day

Sponsors & Collaborators

Principal Investigators

  • Leonard Siew, MD · Quintiles London, UK

  • Bengt Larsson, MD · Astrazeneca Mölndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01962935 on ClinicalTrials.gov